We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam (ALNY) Reports Positive Data for RNAi Candidate
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced positive results from phase I and phase I/II open-label extension (OLE) studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias (AHPs).
Shares of the company increased 88.1% against the industry’s decline of 8.5%.
Givosiran is an investigational, subcutaneously administered RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1).
The double-blind, placebo-controlled phase I study showed that compared with a once quarterly dose regimen, monthly dosing led to an over 80% lowering of urinary aminolevulinic acid (“ALA”), a disease biomarker, and an over 75% decrease in mean annualized porphyria attack rate, relative to placebo. Increasing the monthly dose from 2.5 mg/kg to 5.0 mg/kg did not lead to further lowering of ALA and PBG levels.
Monthly dosing regimens led to increased clinical activity as compared to quarterly dosing. A continuous relationship between greater ALA lowering and AAR reduction was also observed.
The study showed enhanced clinical activity with long-term treatment of up to 22 months in the ongoing phase I/II OLE study, with an over 90% decrease in mean annualized porphyria attack rate, relative to baseline run-in attack rate. The extent of these reductions in the OLE study exceeded that observed in response to givosiran treatment during the phase I study, suggesting that extended dosing at 2.5 mg/kg monthly potentially leads to enhanced clinical activity.
Clinical activity and safety results support accelerated efforts to bring givosiran to patients with acute hepatic porphyrias.
The company also announced that that it will continue to enroll patients in the ENVISION phase III pivotal study, which was initiated at the end of 2017. The company also expects to enroll the thirtieth patient into ENVISION in the coming weeks in support of the planned interim analysis in mid-2018, which, if positive, would support a potential new drug application filing for givosiran by end of 2018.
A few better-ranked stocks from the same space worth considering are Ligand Pharmaceuticals (LGND - Free Report) , Protagonist Therapeutics (PTGX - Free Report) and Catabasis Pharmaceuticals . Whlle Ligand and Protagonist sport a Zacks Rank #1 (Strong Buy), Catabasis carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up $3.78 to $4.40 from $4.75 to $5.32 for 2018 and 2019, respectively, over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 57% over a year.
Protagonist’s loss estimates narrowed from $1.30 to 66 cents for 2018 and from $1.99 to $1.26 for 2019, over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.95%.
Catabasis’ loss estimates narrowed from $1.09 to 92 cents for 2018 and from $1.76 to $1.48 for 2019, in the last 30 days. The company came up with a positive earnings surprise in all the preceding four quarters, with an average beat of 14.56%. The stock has rallied 23.9% so far this year.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Image: Bigstock
Alnylam (ALNY) Reports Positive Data for RNAi Candidate
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced positive results from phase I and phase I/II open-label extension (OLE) studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias (AHPs).
Shares of the company increased 88.1% against the industry’s decline of 8.5%.
Givosiran is an investigational, subcutaneously administered RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1).
The double-blind, placebo-controlled phase I study showed that compared with a once quarterly dose regimen, monthly dosing led to an over 80% lowering of urinary aminolevulinic acid (“ALA”), a disease biomarker, and an over 75% decrease in mean annualized porphyria attack rate, relative to placebo. Increasing the monthly dose from 2.5 mg/kg to 5.0 mg/kg did not lead to further lowering of ALA and PBG levels.
Monthly dosing regimens led to increased clinical activity as compared to quarterly dosing. A continuous relationship between greater ALA lowering and AAR reduction was also observed.
The study showed enhanced clinical activity with long-term treatment of up to 22 months in the ongoing phase I/II OLE study, with an over 90% decrease in mean annualized porphyria attack rate, relative to baseline run-in attack rate. The extent of these reductions in the OLE study exceeded that observed in response to givosiran treatment during the phase I study, suggesting that extended dosing at 2.5 mg/kg monthly potentially leads to enhanced clinical activity.
Clinical activity and safety results support accelerated efforts to bring givosiran to patients with acute hepatic porphyrias.
The company also announced that that it will continue to enroll patients in the ENVISION phase III pivotal study, which was initiated at the end of 2017. The company also expects to enroll the thirtieth patient into ENVISION in the coming weeks in support of the planned interim analysis in mid-2018, which, if positive, would support a potential new drug application filing for givosiran by end of 2018.
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. Price | Alnylam Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Alnylam carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the same space worth considering are Ligand Pharmaceuticals (LGND - Free Report) , Protagonist Therapeutics (PTGX - Free Report) and Catabasis Pharmaceuticals . Whlle Ligand and Protagonist sport a Zacks Rank #1 (Strong Buy), Catabasis carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up $3.78 to $4.40 from $4.75 to $5.32 for 2018 and 2019, respectively, over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 57% over a year.
Protagonist’s loss estimates narrowed from $1.30 to 66 cents for 2018 and from $1.99 to $1.26 for 2019, over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.95%.
Catabasis’ loss estimates narrowed from $1.09 to 92 cents for 2018 and from $1.76 to $1.48 for 2019, in the last 30 days. The company came up with a positive earnings surprise in all the preceding four quarters, with an average beat of 14.56%. The stock has rallied 23.9% so far this year.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Click here to access these stocks>>